Neuronetics Inc
STIM
View Detailed Chart
1.560USD
+0.140+9.86%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
106.77MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+9.86%
5 Days
-25.36%
1 Month
-7.69%
6 Months
-63.25%
Year to Date
+13.04%
1 Year
-56.18%
View Detailed Chart
TradingKey Stock Score of Neuronetics Inc
Currency: USD Updated: 2026-02-06Key Insights
Neuronetics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 89 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neuronetics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Neuronetics Inc Highlights
StrengthsRisks
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Growing
The company is in a growing phase, with the latest annual income totaling USD 74.89M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 74.89M.
Fairly Valued
The company’s latest PE is -1.88, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.40M shares, decreasing 26.69% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 13.74K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.95.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
6.500
Target Price
+357.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Neuronetics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neuronetics Inc Info
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Ticker SymbolSTIM
CompanyNeuronetics Inc
CEOMr. Keith J. Sullivan
Websitehttps://neurostar.com/neuronetics/
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68444.000
-1526.130 (-2.18%)
282.580
+22.390 (+8.61%)
2011.850
-39.880 (-1.94%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
